These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18697851)

  • 21. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 22. Discussion of paper by Korn and Freidlin.
    Wittes J
    Am J Bioeth; 2011 Mar; 11(3):13-4. PubMed ID: 21400376
    [No Abstract]   [Full Text] [Related]  

  • 23. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 24. Monitoring clinical trials. Several points are contentious.
    Parry D
    BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778590
    [No Abstract]   [Full Text] [Related]  

  • 25. Randomized trials or population-based registries.
    Bergqvist D; Björck M; Säwe J; Troëng T
    Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):253-6. PubMed ID: 17689818
    [No Abstract]   [Full Text] [Related]  

  • 26. Monitoring clinical trials. Interim data should not be publicly available.
    Richards SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11778588
    [No Abstract]   [Full Text] [Related]  

  • 27. Monitoring clinical trials. Caution may be warranted in releasing interim trial data.
    Thornton H
    BMJ; 2001 Dec; 323(7326):1424-5. PubMed ID: 11778589
    [No Abstract]   [Full Text] [Related]  

  • 28. Comments about the prospective randomized trial by Aoyama et al.
    Patchell RA; Regine WF; Renschler M; Loeffler JS; Sawaya R; Chin LS; Andrews DW
    Surg Neurol; 2006 Nov; 66(5):459-60. PubMed ID: 17084184
    [No Abstract]   [Full Text] [Related]  

  • 29. Sequential monitoring of randomization tests: stratified randomization.
    Zhang Y; Rosenberger WF; Smythe RT
    Biometrics; 2007 Sep; 63(3):865-72. PubMed ID: 17825016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials.
    Tharmanathan P; Calvert MJ; Freemantle N
    J Clin Pharm Ther; 2006 Apr; 31(2):111-8. PubMed ID: 16635044
    [No Abstract]   [Full Text] [Related]  

  • 31. Management and interpretation of data obtained from clinical trials in pain management.
    Theodore BR; Gatchel RJ
    Pain Pract; 2008; 8(6):461-72. PubMed ID: 19000174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus?
    Richert L; Bouteloup V; Thiébaut R; Chêne G
    AIDS; 2008 May; 22(8):996-7. PubMed ID: 18453863
    [No Abstract]   [Full Text] [Related]  

  • 33. Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.
    Bird SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11744570
    [No Abstract]   [Full Text] [Related]  

  • 34. When should an interim analysis be unblinded to the data monitoring committee?
    Knottnerus JA; Spigt MG
    J Clin Epidemiol; 2010 Apr; 63(4):350-2. PubMed ID: 19762210
    [No Abstract]   [Full Text] [Related]  

  • 35. Rashomon revisited: two views of monitoring the Women's Health Initiative trials.
    Goodman SN
    Clin Trials; 2007; 4(3):205-6. PubMed ID: 17715245
    [No Abstract]   [Full Text] [Related]  

  • 36. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 37. ALS issues in clinical trials. Missing data.
    Thompson JL; Levy G
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():48-51. PubMed ID: 15512872
    [No Abstract]   [Full Text] [Related]  

  • 38. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Fox guarding the clinical trial: internal vs. external validity in randomized studies.
    Goodwin PJ; Pritchard KI; Spiegel D
    Psychooncology; 1999; 8(3):275. PubMed ID: 10390742
    [No Abstract]   [Full Text] [Related]  

  • 40. Limitations of randomized clinical trials in chronic diseases: explanations and recommendations.
    Pincus T
    Adv Mind Body Med; 2002; 18(2):14-21. PubMed ID: 12629874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.